TG Therapeutics Inc. (NASDAQ:TGTX) was up 14.8% on Wednesday . The stock traded as high as $7.22 and last traded at $7.14, with a volume of 832,087 shares traded. The stock had previously closed at $6.22.

Several equities research analysts have weighed in on TGTX shares. FBR & Co reiterated a “buy” rating on shares of TG Therapeutics in a report on Wednesday, May 4th. Zacks Investment Research cut TG Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 10th. SunTrust Banks Inc. started coverage on TG Therapeutics in a report on Friday, May 27th. They issued a “buy” rating and a $18.00 target price for the company. Brean Capital reissued a “buy” rating on shares of TG Therapeutics in a research report on Tuesday, May 31st. Finally, Roth Capital reissued a “buy” rating and issued a $33.00 price target on shares of TG Therapeutics in a research report on Thursday, June 9th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $22.75.

The company has a 50-day moving average of $5.96 and a 200-day moving average of $7.68. The company’s market capitalization is $385.27 million.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by $0.04. On average, equities research analysts anticipate that TG Therapeutics Inc. will post ($1.23) earnings per share for the current year.

A hedge fund recently raised its stake in TG Therapeutics stock. New York State Common Retirement Fund raised its stake in TG Therapeutics Inc. (NASDAQ:TGTX) by 23.7% during the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 223,851 shares of the biopharmaceutical company’s stock after buying an additional 42,933 shares during the period. New York State Common Retirement Fund owned 0.43% of TG Therapeutics worth $2,671,000 at the end of the most recent reporting period.

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.